Accelerated Biosciences Announces License of its Human Trophoblast Stem Cells (hTSC) to Agathos Biologics for Development of Ethically Sourced Research and Biomanufacturing Platforms
News
Accelerated Biosciences and Spanios Partner to Advance Therapeutic Design Across Solid Tumor Cancers
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer
Mekonos Enters Partnership Agreement with Accelerated Biosciences to Develop and Commercialize Engineered Human Trophoblast Stem Cells (hTSCs) for Biomanufacturing
– Mekonos’ silicon nanoneedle-based delivery platform will provide Accelerated Bio with high efficiency, high viability cell engineering – including the precise and gentle delivery of multiplexed genetic cargo into its pluripotent hTSCs
– Accelerated Bio’s ethically derived and multi-functional hTSCs offer manufacturers a scalable and robust foundation for next-generation biomanufacturing
– Using Mekonos’ technology, Accelerated Bio will bypass the limitations of conventional delivery approaches like electroporation, for improved non-viral delivery into its fragile stem cells
SIRPant Immunotherapeutics to Participate in Wells Fargo Virtual Private Biotech Symposium
Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway
Melior Is Recognized as CRO of the Year by Life Sciences Review
Life Sciences Review annually selects 10 preeminent CROs and has chosen Melior Discovery as the top CRO in 2023
The editors recognized Melior’s unique capabilities in the pre-clinical in vivo pharmacology space with its theraTRACE offering, its breadth of model offerings, and boutique client interaction experience
SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma